Advertisement

Topics

Latest Biological Therapy NewsRSS

10:05 EDT 20th October 2017 | BioPortfolio

Ajinomoto Althea Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102017] Prices from USD $250

SummaryAjinomoto Althea Inc Ajinomoto Althea offers contract manufacturing and contract development services to pharmaceutical and biotechnology industries. The service portfolio of the company includes process development, drug substance manufacturing platforms, microbial cell banking, phaseappropriate analytical development and validation, and drug product manufacturing. Its services also includ...

NHS England to increase biosimilar usage

On 12 September 2017, National Health Service (NHS) England released a ‘Commissioning framework for biological medicines (including biosimilar medicines)’. In this document, they make a series of recommendations with the aim of increasing both biological and biosimilar uptake. As a result of increased competition between biologicals, creating better value biological medicines and biosimil...

Legionella Testing Market 2021: Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities [Report Updated: 13092017] Prices from USD $4350

The report presents a detailed analysis of the Legionella diagnostics market in the US, Europe France, Germany, Italy, Spain, UK and Japan. Current scientific views on the Legionella definition, epidemiology and etiology are reviewed. The report provides the 5year test volume and sales forecasts by country for the following market segments:nbsp; nbsp; nbsp; Hospitalsnbsp; nbsp; nbsp; Commercial/...

Campylobacter Testing Market 2021: Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities [Report Updated: 13092017] Prices from USD $4350

The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe France, Germany, Italy, Spain, UK and Japan. Current scientific views on the Campylobacter definition, epidemiology and etiology are reviewed. The report provides the 5year test volume and sales forecasts by country for the following market segments:nbsp; nbsp; nbsp; Hospitalsnbsp; nbsp; nbsp; Comme...

Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017

SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing TACTI-mel Phase 1 clinical trial in metastatic melanoma at the World Immunotherapy Congress 2017 in Basel, Switzerland at 5.50pm CES...

Enterovirus Testing Market 2021: Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities [Report Updated: 13092017] Prices from USD $4350

The report presents a detailed analysis of the Enterovirus diagnostics market in the US, Europe France, Germany, Italy, Spain, UK and Japan. Current scientific views on the Enterovirus definition, epidemiology and etiology are reviewed. The report provides the 5year test volume and sales forecasts by country for the following market segments:nbsp; nbsp; nbsp; Hospitalsnbsp; nbsp; nbsp; Commercia...

Merck cyber attack may cost insurers US$275 million: Verisk's PCS

NEW YORK: Insurers could pay US$275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines.

Aeromonads Diagnostic Testing Market 2021: Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities [Report Updated: 13092017] Prices from USD $4350

The report presents a detailed analysis of the Aeromonads diagnostics market in the US, Europe France, Germany, Italy, Spain, UK and Japan. Current scientific views on the Aeromonads definition, epidemiology and etiology are reviewed. The report provides the 5year test volume and sales forecasts by country for the following market segments:nbsp; nbsp; nbsp; Hospitalsnbsp; nbsp; nbsp; Commercial/Pr...

Moderna Named One of Global Biopharmaceutical Industry’s Top Employers in Science Magazine’s Annual Survey

Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has been named one of the global biopharmaceutical industry’s top employers in Science’s and Science Careers’ 2017 Top Employers Survey. The...

Proteintech Europe Ltd Awarded new SUPC Antibodies and Sera Framework Agreement

Proteintech Europe Ltd, a direct manufacturer of antibodies, has been selected as a trusted supplier of research-grade antibodies as part of the new SUPC (Southern Universities Purchasing Consortium) Antibodies and Sera Inter Regional Laboratories Agreement. The UK-wide framework agreement supplies 6 higher education consortia, members of which in...

Medicago Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummaryMedicago Inc Medicago, a subsidiary of Mitsubishi Tanabe Pharma Corp is a biopharmaceutical company that develops and produces vaccines and antibodies. The company concentrates on the discovery and development of novel vaccines and therapeutic proteins for infectious diseases. Its pipeline products includes pandemic flu vaccine and seasonal flu vaccines. Medicago's seasonal flu vaccine is u...

Juno taps Trianni for mAb discovery platform

Juno Therapeutics has signed a licensing agreement with Trianni for use of its monoclonal antibody (mAb) discovery platform.

Italy Hepatitis Diagnostic Testing Market 2021: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities [Report Updated: 13092017] Prices from USD $3900

Complete report $3,900.nbsp; DataPack test volumes, sales forecasts, supplier shares $2,500.The report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides fiveyear test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, AntiHBc, AntiHBs, AntiHAV, Hepat...

Global Bacillus Subtilis Market Research Report 20112023 [Report Updated: 28092017] Prices from USD $2160

SummaryBacillus subtilis, known also as the hay bacillus or grass bacillus, is a Grampositive, catalasepositive bacterium, found in soil and the gastrointestinal tract of ruminants and humans. A member of the genus Bacillus, B. subtilis is rodshaped, and can form a tough, protective endospore, allowing it to tolerate extreme environmental conditions. B. subtilis has historically been classified as...

Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings

— Poster Presentations Will Discuss Global Screening Data from Aimmune’s Phase 3 PALISADE Trial and Current Approaches to Oral Immunotherapy — Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy duri...

Rubella Testing Market 2021: Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities [Report Updated: 13092017] Prices from USD $4350

The report presents a detailed analysis of the Rubella diagnostics market in the US, Europe, France, Germany, Italy, Spain, UK and Japan. Current scientific views on the Rubella definition, epidemiology and etiology are reviewed. The report provides the 5year test volume and sales forecasts by country for the following market segments:nbsp; nbsp; nbsp; Hospitalsnbsp; nbsp; nbsp; Commercial/Priva...

Vanderbilt Researchers Find Novel Mechanism Of Resistance To Anti-Cancer Drugs

NewsSome targeted anti-cancer therapies are mainstays of treatment for advanced colorectal cancer. However, many patients have tumors with genetic mutations that make them resistant to these antibodies, or the cancers develop resistance during treatment.

Abzena and UGA Biopharma partner to develop a cell line expressing a biosimilar therapeutic for Multiple Sclerosis.

Cambridge, UK, and Hennigsdorf, Germany 19 September 2017 – Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell...

DCPrime and apceth Biopharma GmbH Announce Manufacturing Partnership

    Leiden, The Netherlands, and Munich, Germany, October 19, 2017 / B3C newswire / -- DCPrime BV, a clinical stage company developing dendritic

Global Encephalitis Vaccine, Live Market Research Report Forecast 2017 to 2021 [Report Updated: 18092017] Prices from USD $2800

The Global Encephalitis Vaccine, Live Market Research Report Forecast 20172021 is a valuable source of insightful data for business strategists. It provides the Encephalitis Vaccine, Live industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elaborate description of the value chain and its distributor...

Why did one-quarter of patients in one study stop taking their biosimilar? Subjective health complaints say experts

One-quarter (24%) of people who were switched from infliximab to a biosimilar version stopped taking the biosimilar due to health complaints during a six-month follow-up period, highlights research in Arthritis & Rheumatology. A biosimilar is a biological medicine that shows no clinically meaningful differences with an approved biological medicine. Healthcare systems around the world are [R...

Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis

Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line to treat Multiple Sclerosis (MS). ...

AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication

The drug will be developed by Roivant in a new therapeutic area that is outside of AstraZeneca's main therapy areas.

The Re-emergence of Gemtuzumab Ozogamicin for AML

Today we are speaking with Jorge Cortes, MD, who specializes in the treatment and clinical research of leukemia at M.D. Anderson Cancer Center in Houston, Texas, about treatment of patients with acute myeloid leukemia (AML) in the context of a new drug approval for the disease. Gemtuzumab ozogamicin (Mylotarg) an antibody drug conjugate, consisting of a recombinant, humanized anti-CD33 monoclonal ...

OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model FR104 efficacious in graft-versus-host reaction in bone marrow transplant model NANTES, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE), today announces the positive results of two preclinical studies evaluating FR104, an anti-antagonist antibody o...

Quick Search
Advertisement
 

review and buy Biological Therapy market research data and corporate reports here